Annovis Bio, Inc., a clinical-stage pharmaceutical company, is dedicated to developing treatments for neurodegenerative disorders, including Alzheimer’s disease (AD) and Parkinson’s disease (PD). The company’s flagship drug candidate, Buntanetap, is being designed to tackle these devastating conditions, with the potential to treat other chronic neurodegenerative diseases as well.

In addition to Buntanetap, Annovis Bio has a promising pipeline that includes two additional product candidates, ANVS405 and ANVS301. These drugs are aimed at treating traumatic brain injuries, strokes, and advanced stages of Alzheimer’s disease. Each of these potential therapies is designed to address the underlying causes of these conditions, offering new hope for patients who have limited treatment options.

Annovis Bio was established in May 2008 by Maria Luisa Maccecchini, a visionary in the field of neurological research. The company is headquartered in Malvern, Pennsylvania, where it continues to focus on bringing innovative treatments to market for patients suffering from some of the most debilitating neurodegenerative diseases.

With a strong focus on clinical research and drug development, Annovis Bio is positioning itself at the forefront of neurological disease treatment. As clinical trials for Buntanetap and other candidates progress, the company remains committed to addressing unmet medical needs and improving patient outcomes.

The company’s stock, currently valued at $8.22, reflects the growing interest in its potential to revolutionize treatments for neurodegenerative diseases.